J9031 – Bcg (intravesical) per instillation
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9031
- Long description
- Bcg (intravesical) per instillation
- Short description
- Bcg live intravesical vac
- Pricing indicator
51Drugs- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1DChemotherapy- Added
- January 1, 1991
- Last change
- July 1, 2019 – No change
- Termination date
- June 30, 2019
Frequently asked questions
What is HCPCS code J9031?
J9031 is a HCPCS Level II code for bcg (intravesical) per instillation. It was discontinued on June 30, 2019.
Does Medicare cover J9031?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9023 – Injection, avelumab, 10 mg
- J9024 – Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025 – Injection, azacitidine, 1 mg
- J9026 – Injection, tarlatamab-dlle, 1 mg
- J9027 – Injection, clofarabine, 1 mg
- J9028 – Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
- J9029 – Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose
- J9030 – Bcg live intravesical instillation, 1 mg
- J9032 – Injection, belinostat, 10 mg
- J9033 – Injection, bendamustine hydrochloride, not otherwise specified, 1 mg
- J9034 – Injection, bendamustine hcl (bendeka), 1 mg
- J9035 – Injection, bevacizumab, 10 mg
- J9036 – Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg
- J9037 – Injection, belantamab mafodotin-blmf, 0.5 mg
- J9038 – Injection, axatilimab-csfr, 0.1 mg
- J9039 – Injection, blinatumomab, 1 microgram
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.